IP Library Granted Patent US 9,907,879
Granted Patent B2
US 9,907,879 · App. 15/032,485 · Granted Mar 6, 2018

Haemostatic composition comprising crystalline polyphosphate

Inventors: Henrike Thauern (Weinheim, DE); Thomas Staffel (Grunstadt, DE)
Assignee: BK GIULINI GMBH
A61L24/02A61L15/18A61L15/44A61L24/08A61L24/106A61L24/108A61L26/0004A61L26/0066A61L2300/112A61L2300/418A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,879
App. No.
15/032,485
Granted
Mar 6, 2018
Kind
B2
Abstract

The present invention relates to the use of polyphosphate in crystalline form for treatment of wounds, especially bleeding wounds, wherein the anion of the polyphosphate has a (numerical) average of at least 4 phosphorus atoms per polyphosphate anion. The invention additionally relates to a composition suitable for treatment of wounds, especially bleeding wounds, comprising an inventive polyphosphate and a carrier material. The invention further provides a method suitable for production of the inventive composition, which comprises the introduction of the polyphosphate and optionally further haemostatic agents into the carrier material, or into a component or into a precursor of the carrier material.

Claims (14)

1. A method for treating bleeding wounds comprising applying a composition that comprises a polyphosphate in crystalline form, wherein an anion of the polyphosphate has on average (number average) at least 4 phosphorus atoms per polyphosphate anion, and wherein the crystalline polyphosphate is substantially water-insoluble.

2. The method of claim 1 , wherein the polyphosphate has a degree of crystallinity, determined by X-ray diffractometry, of at least 90%.

3. The method of claim 2 , wherein the anion of the polyphosphate is substantially linear.

4. The method of claim 1 , wherein the polyphosphate anion has on average from 8 to 500 phosphorus atoms.

5. The method of claim 1 , wherein cations of the polyphosphate are independently selected from Na + , K + , NH 4 + , Ca 2+ , Mg 2+ , Zn 2+ , Sn 2+ , Fe 3+ and Al 3+ .

6. The method of claim 5 , wherein the cations of the polyphosphate are selected from Na + , K + , NH 4 + and Ca 2+ .

7. The method of claim 1 , wherein particles of the crystalline polyphosphate have a weight-average particle size within the range of 1 μm to 1 mm.

8. The method of claim 2 , wherein the degree of crystallinity is at least 95%.

9. The method of claim 1 , wherein the polyphosphate anion has an average 12 to 300 phosphorus atoms.

10. The method of claim 1 , wherein the polyphosphate anion has an average 15 to 150 phosphorus atoms.

11. The method of claim 7 , wherein the particles of the crystalline polyphosphate have a weight-average particle size within the range of 1 mm to 0.5 mm.

12. The method of claim 6 , wherein the cations of the polyphosphate are selected from Na + , K + and NH 4 + .

13. The method of claim 1 , wherein the polyphosphate has a degree of crystallinity of at least 95% as determined by X-ray diffractometry, wherein the polyphosphate anion has on average from 15 to 150 phosphorus atoms; and wherein the cations of the polyphosphate are selected from Na + , K + , NH 4 + and Ca 2+ .

14. The method of claim 13 , wherein the cations of the polyphosphate are selected from Na + , K + and NH 4 + .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: THAUERN, HENRIKE; STAFFEL, THOMAS
To: BK GIULINI GMBH
Reel/Frame 039510/0534 →
Priority Claims (1)
DE 10 2013 222 223 · Oct 31, 2013 · national
Continuity (1)
Related Publication 20160263275A1 · Sep 15, 2016